关于举办 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日在巨潮资讯网上披露了《2024 年年度报告》及《2024 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营 业绩、发展战略等情况，公司定于 2025 年 5 月 15 日（星期四） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办 2024 年度 网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 关于举办 2024 年度网上业绩说明会的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-024 广州迈普再生医学科技股份有限公司 董事、副总经理、财务总监 骆雅红女士 董事、副总经理、董事会秘书 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock to outperform the benchmark index by over 20% in the next six months [15]. Core Insights - The company has shown a continuous increase in the proportion of new products, indicating the emergence of a second growth curve [3]. - In 2024, the company achieved a revenue of 278 million yuan, a year-on-year increase of 20.61%, and a net profit attributable to the parent company of 79 million yuan, up 92.90% year-on-year [3][4]. - The company’s new products, including artificial dura mater patches and craniofacial repair systems, accounted for 56%, 29%, and 13% of revenue respectively in 2024 [4]. - The company is focusing on expanding its influence in KA hospitals and enhancing its academic system in neurosurgery [6][8]. Financial Performance - The company’s revenue for Q1 2025 was 74 million yuan, reflecting a year-on-year growth of 28.84%, with a net profit of 24 million yuan, up 61.68% [3]. - The projected revenue for 2025-2027 is expected to be 364 million yuan, 489 million yuan, and 657 million yuan, with year-on-year growth rates of 30.7%, 34.3%, and 34.4% respectively [9][11]. - The net profit attributable to the parent company for the same period is forecasted to be 115 million yuan, 166 million yuan, and 237 million yuan, with growth rates of 46.3%, 43.9%, and 42.9% [9][11]. Product Development and Market Strategy - The company’s hemostatic gauze product has expanded its application from neurosurgery to general surgery, significantly broadening its clinical use [5]. - The hard dura mater medical glue received EU MDR certification, which is expected to enhance the company’s revenue share in overseas markets [5]. - The company plans to deepen its market presence domestically while also expanding internationally, aiming to increase brand influence and market penetration [8].

Investment Rating - The investment rating for the company is "Buy" [7][15]. Core Views - The company has shown a continuous increase in the proportion of new products, indicating the emergence of a second growth curve [3][4]. - In 2024, the company achieved a revenue of 278 million yuan, a year-on-year increase of 20.61%, and a net profit attributable to the parent company of 79 million yuan, a year-on-year increase of 92.90% [3][11]. - The company is focusing on expanding its product influence in KA hospitals and aims to enhance its market penetration both domestically and internationally [6][8]. Financial Performance - In Q1 2025, the company reported a revenue of 74 million yuan, a year-on-year increase of 28.84%, and a net profit of 24 million yuan, a year-on-year increase of 61.68% [3][4]. - The sales revenue from the craniofacial repair and fixation system reached approximately 79.9 million yuan in 2024, growing by 31.05% compared to the previous year [4][5]. - The company expects revenues for 2025 to reach 364 million yuan, with a year-on-year growth rate of 30.7%, and net profits to be 115 million yuan, with a growth rate of 46.3% [9][11]. Product Development - The sales revenue from absorbable regenerated oxidized cellulose and dural glue reached approximately 36 million yuan in 2024, marking a growth of 49.89% [5]. - The company has expanded the application range of its hemostatic gauze products and successfully obtained EU registration for its dural glue, which is expected to enhance its revenue share in overseas markets [5][6]. Market Strategy - The company plans to build an academic system around two main themes: standardized management of cerebrospinal fluid leaks and cranial repair practices, to enhance its product solution influence in neurosurgery [8]. - The company aims to optimize costs and improve production efficiency to ensure product quality and maintain market responsiveness [8].

股份质押的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-023 广州迈普再生医学科技股份有限公司 关于公司实际控制人、控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）近日 接到公司实际控制人、控股股东袁玉宇先生的函告，获悉其所持有的 公司部分股份办理了质押登记手续，具体情况如下： 注：1、上述质押股份不负担重大资产重组等业绩补偿义务； 2、本公告中的无限售条件流通股包括高管锁定股，不存在股份 冻结情形，下同； 3、公司目前总股本为 66,519,431 股（含回购股份）。 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质 押数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 是否 为限 售股 是否 为补 充质 押 质押 起始 日 质押到期 日期 质权人 质押 用途 袁玉宇 是 410,00 0 3.73 0.62 否 否 2025- 04-28 至办理解 除质押日 结束 王羽琳 个人 融资 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue and profit growth projections. Core Insights - The company reported a revenue of 278 million yuan in 2024, representing a year-over-year increase of 20.61%, with a net profit of 79 million yuan, up 92.9% year-over-year [1][2] - The core product, artificial dura mater patches, generated 156 million yuan in revenue, reflecting an 11.46% increase, while new products contributed significantly to growth [2] - The company is expanding its market presence both domestically and internationally, with revenues from domestic sales reaching 222 million yuan (up 22.63% YoY) and international sales at 57 million yuan (up 13.28% YoY) [2] Financial Performance Summary - In 2024, the company achieved a net cash flow from operating activities of 116 million yuan, a year-over-year increase of 8.08% [1] - The company’s gross margin is projected to decline slightly from 82.0% in 2023 to 76.2% by 2027, indicating a focus on maintaining profitability despite increased competition [4] - The forecasted revenues for 2025, 2026, and 2027 are 369 million yuan, 488 million yuan, and 637 million yuan, respectively, with corresponding net profits of 114 million yuan, 150 million yuan, and 197 million yuan [4] Market and Product Insights - The company is actively engaging in marketing and brand promotion, having entered nearly 2000 hospitals in China, which enhances its brand influence [2] - The introduction of new products, such as absorbable regenerated oxidized cellulose and dura mater medical glue, is expected to drive future growth [2] - The company has received EU MDR certification for its dura mater medical glue, which is anticipated to enhance its competitiveness in international markets [2]

[Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 迈普医学(301033) 投资评级 上次评级 相关研究 [Table_OtherReport] 集采压力期已过，国内海外双丰收 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 集采助力产品放量，盈利能力逐步增强 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary]2024 年年报和 2025 年一季报，2024 年实现营业收入 2.78 亿元（yoy+20.61%），归母净利润 0.79 亿元（yoy+92.9%），扣非归母净 利润 0.68 亿 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 股东大会通知 证券代码：301033 证券简称：迈普医学 公告编号：2025-022 广州迈普再生医学科技股份有限公司 关于召开 2024 年年度股东大会的通知 一、召开会议的基本情况 （一）股东大会届次：2024 年年度股东大会。 （二）股东大会的召集人：广州迈普再生医学科技股份有限公司 （以下简称"公司"、"迈普医学"）董事会。 （三）会议召开的合法、合规性：公司第三届董事会第八次会议 决议召开本次股东大会。本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 （四）会议召开日期和时间： 1、现场会议召开时间：2025 年 5 月 16 日（星期五）下午 14:30； 2、网络投票日期、时间： （1）通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2025 年 5 月 16 日 9:15—9:25,9:30— 11:30 和 13:00—15:00； （2）通过深交所互联网投票系统（http://wltp.cninfo.com.cn） 投票的具 ...

监事会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-014 广州迈普再生医学科技股份有限公司 第三届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）第三 届监事会第八次会议于 2025 年 4 月 23 日下午 16:00 以现场方式在公 司会议室召开。本次会议通知已于 2025 年 4 月 11 日以书面的方式向 全体监事和相关与会人员发出。会议应出席监事 3 人，实际出席会议 监事 3 人。本次会议由监事会主席莫梅玲女士召集并主持，公司董事 会秘书龙小燕女士列席了会议。本次会议的召集、召开和表决程序符 合国家有关法律、行政法规及《广州迈普再生医学科技股份有限公司 章程》（以下简称"《公司章程》"）的规定，会议形成的决议合法有效。 二、监事会会议审议情况 经与会监事认真审议，以记名投票表决方式通过以下决议： （一）审议通过《关于<2024 年度监事会工作报告>的议案》 2024 年度，公司监事会严格按照国家有关法律、行政法规和《公 ...